Cargando…

In Vitro Testing of the Virus-Like Drug Conjugate Belzupacap Sarotalocan (AU-011) on Uveal Melanoma Suggests BAP1-Related Immunostimulatory Capacity

PURPOSE: The virus-like drug conjugate belzupacap sarotalocan (AU-011), currently under clinical investigation for first-line treatment of primary uveal melanoma (UM), shows enhanced tumor specificity by targeting heparan sulfate proteoglycans (HSPG). Such a treatment may potentially lead to systemi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Sen, Huis In't Veld, Ruben V., Houy, Alexander, Stern, Marc-Henri, Rich, Cadmus, Ossendorp, Ferry A., Jager, Martine J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Association for Research in Vision and Ophthalmology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10246758/
https://www.ncbi.nlm.nih.gov/pubmed/37272766
http://dx.doi.org/10.1167/iovs.64.7.10
_version_ 1785055095927341056
author Ma, Sen
Huis In't Veld, Ruben V.
Houy, Alexander
Stern, Marc-Henri
Rich, Cadmus
Ossendorp, Ferry A.
Jager, Martine J.
author_facet Ma, Sen
Huis In't Veld, Ruben V.
Houy, Alexander
Stern, Marc-Henri
Rich, Cadmus
Ossendorp, Ferry A.
Jager, Martine J.
author_sort Ma, Sen
collection PubMed
description PURPOSE: The virus-like drug conjugate belzupacap sarotalocan (AU-011), currently under clinical investigation for first-line treatment of primary uveal melanoma (UM), shows enhanced tumor specificity by targeting heparan sulfate proteoglycans (HSPG). Such a treatment may potentially lead to systemic immune responses. We studied the potential of AU-011 treatment to induce immunogenic cell death as the first step to induce systemic immunity. METHODS: We determined binding and uptake of AU-011 in ten primary and metastatic UM cell lines. The subcellular location of AU-011 was assessed by fluorescence microscopy. Following light activation (wavelength 690 nm) of AU-011, the half-maximal effective concentration (EC(50)) of AU-011 treatment and exposure of damage-associated molecular patterns (DAMPs) were assessed using flow cytometry. DAMPs were measured by RNAseq. RESULTS: Fluorescence microscopy revealed most of the AU-011 was present in the cytoplasm. AU-011 binding and uptake by UM cells increased over time, with a lower uptake in BAP1-negative than in BAP1-positive cell lines. AU-011 activation induced cell death across all UM cell lines with EC(50) values at picomolar concentrations. The AU-011 concentration and total light dose (J/cm(2)) were the most important parameters for the observed cytotoxicity. Finally, light-activated AU-011 induced exposure of DAMPs calreticulin (CRT) and HSP90. CRT exposure by light-activated AU-011 as well as CRT RNA exposure were lower in BAP1-negative compared to BAP1-positive UM cell lines. CONCLUSIONS: AU-011 treatment at low picomolar range induces immunogenic cell death in all 10 UM cell lines. The in vitro cytotoxicity was accompanied by exposure of DAMPs (HSP90 and CRT), suggesting AU-011 may contribute to the development of systemic immunity and be a suitable candidate for combination with immunotherapy in vivo. AU-011 treatment was more effective against BAP1-positive cell lines, with a lower EC(50) and higher CRT exposure.
format Online
Article
Text
id pubmed-10246758
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The Association for Research in Vision and Ophthalmology
record_format MEDLINE/PubMed
spelling pubmed-102467582023-06-08 In Vitro Testing of the Virus-Like Drug Conjugate Belzupacap Sarotalocan (AU-011) on Uveal Melanoma Suggests BAP1-Related Immunostimulatory Capacity Ma, Sen Huis In't Veld, Ruben V. Houy, Alexander Stern, Marc-Henri Rich, Cadmus Ossendorp, Ferry A. Jager, Martine J. Invest Ophthalmol Vis Sci Anatomy and Pathology/Oncology PURPOSE: The virus-like drug conjugate belzupacap sarotalocan (AU-011), currently under clinical investigation for first-line treatment of primary uveal melanoma (UM), shows enhanced tumor specificity by targeting heparan sulfate proteoglycans (HSPG). Such a treatment may potentially lead to systemic immune responses. We studied the potential of AU-011 treatment to induce immunogenic cell death as the first step to induce systemic immunity. METHODS: We determined binding and uptake of AU-011 in ten primary and metastatic UM cell lines. The subcellular location of AU-011 was assessed by fluorescence microscopy. Following light activation (wavelength 690 nm) of AU-011, the half-maximal effective concentration (EC(50)) of AU-011 treatment and exposure of damage-associated molecular patterns (DAMPs) were assessed using flow cytometry. DAMPs were measured by RNAseq. RESULTS: Fluorescence microscopy revealed most of the AU-011 was present in the cytoplasm. AU-011 binding and uptake by UM cells increased over time, with a lower uptake in BAP1-negative than in BAP1-positive cell lines. AU-011 activation induced cell death across all UM cell lines with EC(50) values at picomolar concentrations. The AU-011 concentration and total light dose (J/cm(2)) were the most important parameters for the observed cytotoxicity. Finally, light-activated AU-011 induced exposure of DAMPs calreticulin (CRT) and HSP90. CRT exposure by light-activated AU-011 as well as CRT RNA exposure were lower in BAP1-negative compared to BAP1-positive UM cell lines. CONCLUSIONS: AU-011 treatment at low picomolar range induces immunogenic cell death in all 10 UM cell lines. The in vitro cytotoxicity was accompanied by exposure of DAMPs (HSP90 and CRT), suggesting AU-011 may contribute to the development of systemic immunity and be a suitable candidate for combination with immunotherapy in vivo. AU-011 treatment was more effective against BAP1-positive cell lines, with a lower EC(50) and higher CRT exposure. The Association for Research in Vision and Ophthalmology 2023-06-05 /pmc/articles/PMC10246758/ /pubmed/37272766 http://dx.doi.org/10.1167/iovs.64.7.10 Text en Copyright 2023 The Authors https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License.
spellingShingle Anatomy and Pathology/Oncology
Ma, Sen
Huis In't Veld, Ruben V.
Houy, Alexander
Stern, Marc-Henri
Rich, Cadmus
Ossendorp, Ferry A.
Jager, Martine J.
In Vitro Testing of the Virus-Like Drug Conjugate Belzupacap Sarotalocan (AU-011) on Uveal Melanoma Suggests BAP1-Related Immunostimulatory Capacity
title In Vitro Testing of the Virus-Like Drug Conjugate Belzupacap Sarotalocan (AU-011) on Uveal Melanoma Suggests BAP1-Related Immunostimulatory Capacity
title_full In Vitro Testing of the Virus-Like Drug Conjugate Belzupacap Sarotalocan (AU-011) on Uveal Melanoma Suggests BAP1-Related Immunostimulatory Capacity
title_fullStr In Vitro Testing of the Virus-Like Drug Conjugate Belzupacap Sarotalocan (AU-011) on Uveal Melanoma Suggests BAP1-Related Immunostimulatory Capacity
title_full_unstemmed In Vitro Testing of the Virus-Like Drug Conjugate Belzupacap Sarotalocan (AU-011) on Uveal Melanoma Suggests BAP1-Related Immunostimulatory Capacity
title_short In Vitro Testing of the Virus-Like Drug Conjugate Belzupacap Sarotalocan (AU-011) on Uveal Melanoma Suggests BAP1-Related Immunostimulatory Capacity
title_sort in vitro testing of the virus-like drug conjugate belzupacap sarotalocan (au-011) on uveal melanoma suggests bap1-related immunostimulatory capacity
topic Anatomy and Pathology/Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10246758/
https://www.ncbi.nlm.nih.gov/pubmed/37272766
http://dx.doi.org/10.1167/iovs.64.7.10
work_keys_str_mv AT masen invitrotestingoftheviruslikedrugconjugatebelzupacapsarotalocanau011onuvealmelanomasuggestsbap1relatedimmunostimulatorycapacity
AT huisintveldrubenv invitrotestingoftheviruslikedrugconjugatebelzupacapsarotalocanau011onuvealmelanomasuggestsbap1relatedimmunostimulatorycapacity
AT houyalexander invitrotestingoftheviruslikedrugconjugatebelzupacapsarotalocanau011onuvealmelanomasuggestsbap1relatedimmunostimulatorycapacity
AT sternmarchenri invitrotestingoftheviruslikedrugconjugatebelzupacapsarotalocanau011onuvealmelanomasuggestsbap1relatedimmunostimulatorycapacity
AT richcadmus invitrotestingoftheviruslikedrugconjugatebelzupacapsarotalocanau011onuvealmelanomasuggestsbap1relatedimmunostimulatorycapacity
AT ossendorpferrya invitrotestingoftheviruslikedrugconjugatebelzupacapsarotalocanau011onuvealmelanomasuggestsbap1relatedimmunostimulatorycapacity
AT jagermartinej invitrotestingoftheviruslikedrugconjugatebelzupacapsarotalocanau011onuvealmelanomasuggestsbap1relatedimmunostimulatorycapacity